Personal profile
Education/Academic qualification
Doctorate
3 Jan 1993 → …
Successfully completed an institutional provision in teaching in the higher education sector accredited against the UK Professional Standards Framework
Recognised by Advance HE as a Fellow against Descriptor 2 of the UKPSF
Fingerprint
Dive into the research topics where Helmout Modjtahedi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Decoding drug resistance in cervical cancer cell lines: an AKT-independent mechanism
Bou Antoun, N., Grose, R., Modjtahedi, H., Walker, A. & Chioni, A., Jun 2025, In: Molecular Oncology. 19, S1, p. 367-367 1 p., EACR25-0923.Research output: Contribution to journal › Meeting abstract › peer-review
Open Access -
The co-expression and cellular location of HER family members, EGFRvIII, putative cancer stem cell biomarkers CD44 and CD109 in patients with glioblastoma, and their impacts on prognosis
Mulliqi, E., Khelwatty, S., Bagwan, I., Kamaludin, A., Morgan, A., Long, N., Ashkan, K. & Modjtahedi, H., 4 Apr 2025, In: Cancers. 17, 7, 1221.Research output: Contribution to journal › Article › peer-review
Open Access -
Development and characterization of three novel FGFR inhibitor resistant cervical cancer cell lines to help drive cervical cancer research
Bou Antoun, N., Afshan Mahmood, H. T. N., Walker, A. J., Modjtahedi, H., Grose, R. P. & Chioni, A. M., Mar 2025, In: International Journal of Molecular Sciences. 26, 5, 1799.Research output: Contribution to journal › Article › peer-review
Open AccessFile2 Downloads (Pure) -
Expression of EGFRvIII and its co-expression with wild-type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma
Sherif, O., Khelwatty, S. A., Bagwan, I., Seddon, A. M., Dalgleish, A., Mudan, S. & Modjtahedi, H., Dec 2024, In: Oncology Reports. 52, 6, 172.Research output: Contribution to journal › Article › peer-review
-
The combination of afatinib with dasatinib or miransertib results in synergistic growth inhibition of stomach cancer cells
Al-Janaby, T., Nahi, N., Seddon, A., Bagwan, I., Khelwatty, S. & Modjtahedi, H., Apr 2024, In: World Journal of Oncology. 15, 2, p. 192-208Research output: Contribution to journal › Article › peer-review